Cargando…
Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study
Diabetic kidney disease (DKD) leads to substantial morbidity in patients with type 2 diabetes mellitus (T2DM). Evidence suggests that antidiabetic drug dipeptidyl-peptidase 4 (DPP-4) inhibitors may be able to attenuate albuminuria, whereas the influence of sulfonylureas on albuminuria remains unclea...
Autores principales: | Cheng, Po-Chung, Hsu, Shang-Ren, Kuo, Jeng-Fu, Cheng, Yun-Chung, Liu, Yu-Hsiu, Tu, Shih-Te |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832118/ https://www.ncbi.nlm.nih.gov/pubmed/31627406 http://dx.doi.org/10.3390/jcm8101715 |
Ejemplares similares
-
Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014) -
Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study
por: Lin, Szu Han, et al.
Publicado: (2018) -
Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016) -
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015) -
Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion
por: Das, Ashok K., et al.
Publicado: (2021)